Candriam S.C.A. Roivant Sciences Ltd. Transaction History
Candriam S.C.A.
- $15.6 Billion
- Q1 2025
A detailed history of Candriam S.C.A. transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Candriam S.C.A. holds 27,348 shares of ROIV stock, worth $316,416. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,348Holding current value
$316,416% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ROIV
# of Institutions
323Shares Held
494MCall Options Held
3.67MPut Options Held
754K-
Qvt Financial LP New York, NY65.8MShares$761 Million69.8% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X061.9MShares$716 Million5.69% of portfolio
-
Viking Global Investors LP46MShares$532 Million1.55% of portfolio
-
Vanguard Group Inc Valley Forge, PA40.8MShares$472 Million0.01% of portfolio
-
Morgan Stanley New York, NY35.9MShares$416 Million0.03% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $8.15B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...